Personalized Dendritic Cell Vaccines —Recent Breakthroughs and Encouraging Clinical Results

Conclusions The development and success of DC-based immunotherapies has been hampered by several factors; (1) the immunosuppressive tumor microenvironment, particularly in advanced stage of the disease (2) the limited capacity of systemically administered DC to localize to the tumor-draining lymph nodes, (3) the low avidity of TAAs-specific T cells, and (4) the lack of reliable prognosis biomarkers. The rapidly increasing knowledge about DC subsets and the tumor-induced suppressive microenvironment must be exploited to design novel and improved cancer vaccines. The future of DC vaccines will certainly rely on combination therapies. As discussed in this review, recent studies have shown the great potential of such strategies, especially when using personalized DC vaccines. Overcoming the cancer immunosuppressive environment will reveal the real therapeutic potential of such DC vaccine. Author Contributions BM-G and KB wrote the manuscript. All authors, BM-G, KB, CB, POG, and LEK contributed to manuscript revision, read and approved the submitted version. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments The research leading to these results has received funding from the European Commission's H2020 Programme and the Swiss Government under grant agreement number 635122, and a grant by the Ovacure ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research